查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球液體活檢市場 - 按應用、目標疾病、循環生物標記類型、樣本類型、發展階段、產品類型、技術和主要地區：行業趨勢和全球預測（2018-）2035）
市場調查報告書
商品編碼
1398317

全球液體活檢市場 - 按應用、目標疾病、循環生物標記類型、樣本類型、發展階段、產品類型、技術和主要地區：行業趨勢和全球預測（2018-）2035）

Liquid Biopsy Market : Distribution by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, Stage of Development, Type of Product, & Technique, Key Geographical Regions: Industry Trends & Global Forecasts, 2018-2035
出版日期: | 出版商: Roots Analysis | 英文 331 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

到 2023 年，全球液體切片市場規模將達到 54 億美元，在預測期內（2023-2035 年）複合年增長率為 15.2%。

癌症是全球第二大死因，也是全球健康日益受到關注的問題。 世界衛生組織 (WHO) 預測，到 2040 年，將有 1,630 萬人死於癌症。 在癌症類型中，乳癌是全球最常見的癌症，其次是肺癌、大腸癌和攝護腺癌。 根據監測、流行病學和最終結果（SEER）計劃的統計數據，女性終生乳癌診斷率預計為 18%，預計 2023 年將出現 297,790 例新病例。 為了應對這一日益增長的負擔，許多癌症研究機構正在積極研究針對癌症早期檢測和治療的開創性方法和以患者為中心的策略。 癌症的早期發現是提高治療效果和患者存活率的關鍵因素。 幾十年來，組織活檢一直是癌症診斷的標準。 然而，這種侵入性方法存在不適、疼痛和併發症風險等缺點，阻礙了其廣泛使用。 然而，近年來，液體活檢已被廣泛研究並被認為是一種癌症診斷技術。 特別是在過去的十年裡，液體活檢平台取得了顯著的進步，導致監管部門對微創血液檢測的批准增加。 這些產品提供了一種早期癌症檢測和患者監測的方法，並且易於使用且侵入性極小。 這些測試使用血液樣本和體液（例如尿液和血漿）來識別基因突變和各種循環生物標記物，包括循環腫瘤 DNA、遊離 DNA 和細胞外囊泡。 這種非侵入性評估正在徹底改變癌症治療，特別是對於晚期癌症患者。

本報告分析了全球液體活檢市場，提供了技術概述、市場最新狀況、推動和抑制市場的主要因素、主要資本交易和商業聯盟的近期趨勢以及我們調查的總體情況市場規模趨勢、按細分市場和地區劃分的詳細趨勢以及主要公司的概況。

市場主要參與者

  • Amoy Diagnostics
  • ArcherDX
  • Biocartis
  • Cell Search
  • CellMax Life
  • Datar Cancer Genetics
  • DiaCarta, EONE-DIAGNOMICS
  • Exosome Diagnostics
  • GeneCast Biotechnology
  • Integrated DNA Technologies
  • Lucence
  • MDNA Life Sciences
  • Miltenyi Biotec
  • NeoGenomics
  • ONCODE Scientific
  • OncoDNA
  • QIAGEN
  • PANAGENE
  • Personal Genome Diagnostics
  • Predicin
  • ScreenCell
  • Tecan
  • Thermo Fisher Scientific

目錄

第一章前言

第二章分析方法

第 3 章經濟與其他專案特定考量

  • 分析概述
  • 市場動態

第 4 章執行摘要

第 5 章簡介

  • 分析概述
  • 癌症統計數據和疾病負擔
  • 早期發現癌症的重要性
  • 癌症篩檢與診斷
  • 傳統/侵入性癌症診斷測試
  • 需要非侵入性方法
  • 液體切片：循環生物標記的診斷
  • 與液體活檢和非侵入性檢測相關的成本和效益
  • 無創癌症診斷的最新智慧財產權趨勢
  • 非侵入性癌症診斷面臨的挑戰
  • 未來前景

第 6 章非侵入性癌症篩檢/診斷

  • 分析概述
  • 影像診斷
  • 篩選試驗
  • 先進的非侵入性方法

第 7 章液體切片：市場情勢

  • 分析概述
  • 液體切片產品：整體市場格局
  • 液體切片產品製造商
  • 液體活檢產品：其他液體活檢產品、套件和消耗品
  • 液體活檢產品：合約服務提供商

第八章公司簡介

  • 分析概述
  • 液體活檢市場的其他主要參與者

第 9 章業務夥伴關係/協作

  • 分析概述
  • 業務合作
  • 液體切片：業務合作/協作

第十章融資與投資分析

  • 分析概述
  • 資金類型
  • 液體活檢：融資和投資分析

第十一章產品競爭力分析

  • 分析概述
  • 調查方法
  • 先決條件與關鍵參數
  • 液體切片：產品競爭分析

第十二章主要製藥公司的舉措

  • 分析概述
  • 主要藥廠

第十三章企業收購的主要目標

  • 分析概述
  • 分析範圍/方法
  • 評分標準與重要先決條件
  • 北美的潛在收購目標
  • 歐洲的潛在收購目標
  • 亞太地區和世界其他地區 (ROW) 的潛在收購目標
  • 結論

第14章其他非侵入性癌症診斷

  • 分析概述
  • 非血液生物標記檢測測試
  • FOBT 和糞便免疫化學檢測 (FIT)
  • 色素病變測定
  • 基於糞便 DNA (sDNA) 的測試
  • 揮發性有機化合物（VOC）檢測測試
  • 其他非侵入性癌症診斷：市場狀況

第 15 章市場影響分析：驅動因素、限制、機會、挑戰

  • 分析概述
  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場挑戰
  • 結論

第16章全球液體切片市場

  • 分析概述
  • 主要假設與分析技術
  • 全球非侵入性癌症診斷市場（2023-2035）
  • 全球液體活檢市場：過去趨勢（2018-2022）和預測（2023-2035）
  • 主要細分市場
  • 動態儀表板

第 17 章液體活檢市場：按應用

  • 分析概述
  • 主要假設與分析技術
  • 癌症早期診斷：過去的趨勢（2018-2022）和預測（2023-2035）
  • 病患監測：過去趨勢（2018-2022 年）與預測（2023-2035 年）
  • 重複監測：過去的趨勢（2018-2022 年）與預測（2023-2035 年）
  • 數據測量與驗證

第 18 章液體切片市場：依目標疾病分類

  • 分析概述
  • 主要假設與分析技術
  • 膀胱癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 神經癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 乳癌：過去的趨勢（2018-2022）和預測（2023-2035）
  • 子宮頸癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 頭頸癌：過去趨勢（2018-2022 年）與預測（2023-2035 年）
  • 白血病：過去的趨勢（2018-2022）與預測（2023-2035）
  • 肝癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 肺癌：過去的趨勢（2018-2022）和預測（2023-2035）
  • 黑色素瘤：過去的趨勢（2018-2022 年）與預測（2023-2035 年）
  • 鼻咽癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 食道癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 卵巢癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 胰臟癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 攝護腺癌：過去趨勢（2018-2022 年）與預測（2023-2035 年）
  • 肉瘤：過去的趨勢（2018-2022）和預測（2023-2035）
  • 胃癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 甲狀腺癌：過去的趨勢（2018-2022）與預測（2023-2035）
  • 數據測量與驗證

第 19 章液體切片市場：依循環生物標記類型劃分

  • 分析概述
  • 主要假設與分析技術
  • 無細胞 DNA：過去趨勢（2018-2022 年）與預測估計（2023-2035 年）
  • 循環腫瘤 DNA：過去趨勢（2018-2022 年）和預測估計（2023-2035 年）
  • 細胞外囊泡：過去趨勢（2018-2022 年）和預測估計（2023-2035 年）
  • 其他循環生物標記：歷史趨勢（2018-2022 年）和預測估計（2023-2035 年）
  • 數據測量與驗證

第 20 章液體切片市場：依樣本類型

  • 分析概述
  • 主要假設與分析技術
  • 血液/血漿樣本：過去趨勢（2018-2022 年）和預測（2023-2035 年）
  • 其他範例：過去的趨勢（2018-2022 年）和預測（2023-2035 年）
  • 數據測量與驗證

第 21 章液體切片市場：依最終使用者類型劃分

  • 分析概述
  • 主要假設與分析技術
  • 醫院：過去趨勢（2018-2022 年）與預測（2023-2035 年）
  • 研究機構：過去趨勢（2018-2022）與預測（2023-2035）
  • 其他最終用戶：過去趨勢（2018-2022 年）和預測（2023-2035 年）
  • 數據測量與驗證

第 22 章液體切片市場：依主要地區劃分

  • 分析概述
  • 主要假設與分析技術
  • 北美：過去趨勢（2018-2022 年）與預測（2023-2035 年）
  • 歐洲：過去趨勢（2018-2022 年）與預測（2023-2035 年）
  • 亞太地區和世界其他地區 (ROW)：過去趨勢（2018-2022 年）和預測（2023-2035 年）
  • 數據測量與驗證

第 23 章研究見解

  • 分析概述
  • 受訪者公司的詳細信息
  • 依受訪者立場分析
  • 依產品組合類型進行分析
  • 依所提供的產品/服務類型進行分析
  • 依產品開發階段進行分析
  • 依使用區域分析
  • 依預期市場規模進行分析

第24章結論

第 25 章管理考量

  • 章節概述
  • Foundation for the National Institutes of Health
  • Bahia Software
  • Genostics
  • Oncophenomics
  • Minomic International
  • IVDiagnostics
  • Tymora Analytical Operations
  • ProXeom
  • MiNDERA
  • Resolution Bioscience
  • Nanostics
  • DermTech
  • iCellate Medical
  • VolitionRx
  • OncoDNA
  • LCM Genect
  • Sienna Cancer Diagnostics

第 26 章附錄 1：表格資料

第 27 章附錄 2：公司與組織名單

簡介目錄
Product Code: RA100460

The global liquid biopsy market is valued at USD 5.4 billion in 2023 growing at a CAGR of 15.2% during the forecast period 2023-2035.

Cancer stands as the second most prevalent cause of mortality worldwide, presenting an escalating global health concern. Projections by the World Health Organization (WHO) estimate a staggering 16.3 million cancer-related fatalities by 2040. Among the spectrum of cancer types, breast cancer leads as the most commonly occurring globally, trailed by lung, colorectal, and prostate cancers. Statistical data from the Surveillance, Epidemiology, and End Results (SEER) program indicate an anticipated 18% lifetime diagnosis rate for women regarding breast cancer, with an estimated 297,790 new cases anticipated in 2023. To counteract this mounting burden, numerous cancer research institutions actively engage in pioneering methodologies and patient-centric strategies targeting early detection and treatment of cancer. Early identification of cancer constitutes a pivotal factor in bolstering treatment efficacy and augmenting patient survival rates. For decades, tissue biopsy has stood as the benchmark for cancer diagnosis. However, the drawbacks inherent in this invasive procedure-ranging from discomfort, pain to the risk of complications-have impeded its widespread adoption. Nonetheless, extensive exploration into liquid biopsy over recent years has propelled its acknowledgment as a viable diagnostic technique for cancer. The last decade, in particular, has witnessed remarkable advancements in liquid biopsy platforms, resulting in increased regulatory endorsements for minimally invasive blood-based tests. These products present an avenue for early cancer detection and patient monitoring, offering accessibility and minimal invasiveness. Leveraging blood samples or other bodily fluids like urine or plasma, these tests discern genetic mutations and various circulating biomarkers, encompassing circulating tumor DNA, cell-free DNA, and extracellular vesicles. These non-invasive assessments are revolutionizing cancer care, particularly for individuals in advanced cancer stages.

Key Market Segments:

Application

  • Early Cancer Diagnosis
  • Patient Monitoring
  • Recurrence Monitoring

Type of Target Disease Indication

  • Bladder Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Lung Cancer
  • Prostate cancer
  • Others

Type of Circulating Biomarker

  • Cell Free DNA
  • Cell Free RNA
  • Circulating Tumor DNA
  • Extracellular Vesicles
  • Other Circulating Biomarkers

Type of Sample

  • Blood / Plasma
  • Other Analytes

End User

  • Hospitals
  • Research Institutes
  • Others

Key Geographical Regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the liquid biopsy market based on application, target disease indication, type of circulating biomarker, type of sample, end users, stage of development, type of product, type of technique, application area and key geographical regions
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to four major regions
  • A detailed outline of the research approach employed for studying the liquid biopsy market and non-invasive cancer diagnostics. This includes methodologies, assumptions, and quality control measures adopted to ensure the reliability and accuracy of findings.
  • Examination of historical trends, currency fluctuations, foreign exchange impacts, recessions, and inflation measurements that influence the overall liquid biopsy market.
  • Concise summary capturing key insights from the research, providing a high-level view of the current status of the liquid biopsy market and its anticipated evolution in the short, mid, and long terms.
  • Overview of cancer statistics, emphasizing the global disease burden, the significance of early cancer detection and screening, and insights into different types of circulating biomarkers based on their functionality. Additionally, exploration of emerging trends in intellectual property related to non-invasive cancer diagnostics, liquid biopsy costs, benefits, challenges, and their importance.
  • Emphasis on the necessity and significance of non-invasive cancer diagnostics, inclusive of various imaging techniques, screening assays, advanced diagnostic approaches, along with their respective advantages and disadvantages.
  • Detailed assessment of the liquid biopsy product market based on multiple parameters like development stage, product types (assay kits, devices, software/algorithms), sample types, techniques used, circulating biomarkers, target disease indications, applications, and players involved.
  • Tabulated profiles of leading liquid biopsy companies focusing on their establishment, workforce, headquarters, financial performance, product portfolio, recent developments, and future outlook.
  • Examination of recent collaborations within the liquid biopsy market, considering parameters such as partnership types, circulating biomarkers, target disease indications, most active players, and regional distributions.
  • In-depth analysis of funding and investments in liquid biopsy companies between 2016 and 2023, considering various parameters like funding types, target disease indications, application areas, geographic distribution, leading investors, and notable funding instances.
  • Detailed evaluation of liquid biopsy product competitiveness based on supplier strength, product attributes, company size, and technological advancements.
  • Comprehensive analysis of initiatives by major pharmaceutical companies, focusing on areas of interest, stages of development, product types, target indications, and application areas.
  • Review of historical acquisition activities since 2016, identifying potential acquisition targets within the industry.
  • Detailed insight into various non-invasive diagnostic tests, besides liquid biopsies, offered by different companies for cancer screening and early detection.
  • In-depth examination of growth factors, potential limitations, emerging opportunities, and existing challenges influencing the liquid biopsy market.

Key Benefits of Buying this Report:

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the liquid bipsy market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

  • Amoy Diagnostics
  • ArcherDX
  • Biocartis
  • Cell Search
  • CellMax Life
  • Datar Cancer Genetics
  • DiaCarta, EONE-DIAGNOMICS
  • Exosome Diagnostics
  • GeneCast Biotechnology
  • Integrated DNA Technologies
  • Lucence
  • MDNA Life Sciences
  • Miltenyi Biotec
  • NeoGenomics
  • ONCODE Scientific
  • OncoDNA
  • QIAGEN
  • PANAGENE
  • Personal Genome Diagnostics
  • Predicin
  • ScreenCell
  • Tecan
  • Thermo Fisher Scientific

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Chapter Overview
  • 1.2. Project Objectives
  • 1.3. Scope of the Report
  • 1.4. Inclusions and Exclusions
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Cancer Statistics and Burden of the Disease
  • 5.3. Importance of Early Cancer Detection
  • 5.4. Cancer Screening and Diagnosis
  • 5.5 Conventional Invasive Cancer Diagnostic Tests
    • 5.5.1. Biopsy
    • 5.5.2. Fine Needle Aspiration Biopsy
    • 5.5.3. Core Needle Aspiration Biopsy
    • 5.5.4. Vacuum-Assisted Biopsy
    • 5.5.5. Image Guided Biopsy
    • 5.5.6. Sentinel Node Biopsy
    • 5.5.7. Surgical Biopsy
    • 5.5.8. Endoscopic Biopsy
    • 5.5.9. Bone Marrow Biopsy
    • 5.5.10. Endoscopy
  • 5.6. Need for Non-Invasive Approaches
  • 5.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
    • 5.7.1 Circulating Tumor Cells
    • 5.7.2. Circulating Tumor DNA/ Cell Free DNA
    • 5.7.3. Exosomes
  • 5.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
  • 5.9. Latest Intellectual Property Trends in Non-Invasive Cancer Diagnostics
  • 5.10. Challenges Associated with Non-Invasive Cancer Diagnostics
  • 5.11. Future Perspectives

6. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS

  • 6.1. Chapter Overview
  • 6.2. Diagnostic Imaging
    • 6.2.1. Magnetic Resonance Imaging (MRI)
    • 6.2.2. Mammography
    • 6.2.3. Bone Scan
    • 6.2.4. Computerized Tomography (CT) Scan
    • 6.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
    • 6.2.6. Ultrasound
    • 6.2.7. X-ray Radiography (Barium Enema)
  • 6.3. Screening Assays
    • 6.3.1. Circulating Tumor Marker Test
    • 6.3.2. Digital Rectal Exam (DRE)
    • 6.3.3. Fecal Occult Blood Test (FOBT)
    • 6.3.4. Multigated Acquisition (MUGA) Scan
    • 6.3.5. Papanicolaou Test and Human Papilloma Virus Test
  • 6.4. Advanced Non-Invasive Approaches
    • 6.4.1. Cytogenetic / Gene Expression Studies
    • 6.4.2. Molecular Signature-based Non-Invasive Methods
    • 6.4.3. Saliva-based Oral Cancer Diagnostics
    • 6.4.4. Vital Staining
    • 6.4.5. Optical Biopsy
    • 6.4.6 Other Diagnostic Techniques

7. LIQUID BIOPSY: MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Liquid Biopsy Products: Overall Market Landscape
    • 7.2.1. Analysis by Stage of Development
    • 7.2.2. Analysis by Type of Product
    • 7.2.3. Analysis by Type of Sample
    • 7.2.4. Analysis by Type of Technique
    • 7.2.5. Analysis by Type of Circulating Biomarker
    • 7.2.6. Analysis by Tumor
    • 7.2.7. Analysis by Target Disease Indication
    • 7.2.8. Analysis by Application
    • 7.2.9. Analysis by Application Area
  • 7.3. Liquid Biopsy Product Manufacturers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters (Region)
    • 7.3.3. Analysis by Location of Headquarters (Country)
    • 7.3.4. Most Active Players: Analysis by Number of Liquid Biopsy Products
  • 7.4. Liquid Biopsy Products: Other Liquid Biopsy Products, Kits and Consumables
  • 7.5. Liquid Biopsy Products: Contract Service Providers

8. COMPANY PROFILES

  • 8.1. Chapter Overview
    • 8.2.1. Amoy Diagnostics
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Product Portfolio
      • 8.2.1.3. Recent Developments and Future Outlook
    • 8.2.2. ArcherDX
      • 8.2.2.1. Company Overview
      • 8.2.2.2 Product Portfolio
      • 8.2.2.3. Recent Developments and Future Outlook
    • 8.2.3. DiaCarta
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Product Portfolio
      • 8.2.3.3 Recent Developments and Future Outlook
    • 8.2.4. Integrated DNA Technologies
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Product Portfolio
      • 8.2.4.3. Recent Developments and Future Outlook
    • 8.2.5 MDNA Life Sciences
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Information
      • 8.2.5.3 Product Portfolio
      • 8.2.5.4. Recent Developments and Future Outlook
    • 8.2.6. NeoGenomics
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Product Portfolio
      • 8.2.6.3. Recent Developments and Future Outlook
    • 8.2.7. ONCODE Scientific
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Product Portfolio
      • 8.2.7.3. Recent Developments and Future Outlook
    • 8.2.8. QIAGEN
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Information
      • 8.2.8.3. Product Portfolio
      • 8.2.8.4. Recent Developments and Future Outlook
    • 8.2.9. ScreenCell
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Information
      • 8.2.9.3. Product Portfolio
      • 8.2.9.4. Recent Developments and Future Outlook
    • 8.2.10. Thermo Fisher Scientific
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Information
      • 8.2.10.3. Product Portfolio
      • 8.2.10.4. Recent Developments and Future Outlook
  • 8.3. Other Leading Players in Liquid Biopsy Market
    • 8.3.1. Biocartis
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Product Portfolio
    • 8.3.2. Cell Search
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Product Portfolio
    • 8.3.3. CellMax Life
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Product Portfolio
    • 8.3.4. Datar Cancer Genetics
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Product Portfolio
    • 8.3.5. EONE-DIAGNOMICS Genome Center
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Product Portfolio
    • 8.3.6. Exosome Diagnostics
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Product Portfolio
    • 8.3.7. GeneCast Biotechnology
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Product Portfolio
    • 8.3.8. Inivata
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Product Portfolio
    • 8.3.9. Lucence
      • 8.3.90.1. Company Overview
      • 8.3.9.2. Product Portfolio
    • 8.3.10. Miltenyi Biotec
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Product Portfolio
    • 8.3.11. OncoDNA
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Product Portfolio
    • 8.3.12. PANAGENE
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Product Portfolio
    • 8.3.13. Personal Genome Diagnostics
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Product Portfolio
    • 8.3.14. Predicine
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Product Portfolio
    • 8.3.15. Tecan
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Product Portfolio

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Liquid Biopsy: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Year of Partnership and Type of Partner
    • 9.3.6. Analysis by Type of Partnership and Type of Partner
    • 9.3.7. Analysis by Type of Circulating Biomarker
    • 9.3.8. Analysis by Target Disease Indication
    • 9.3.9. Most Active Players: Analysis by Number of Partnerships
    • 9.3.10. Analysis by Geography
      • 9.3.10.1. Local and International Agreements
      • 9.3.10.2 Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Types of Funding
  • 10.3. Liquid Biopsy: Funding and Investment Analysis
    • 10.3.1. Analysis by Year of Investment
    • 10.3.2. Analysis of Amount Invested by Year
    • 10.3.3. Analysis by Type of Funding
    • 10.3.4. Analysis of Amount Invested by Type of Funding
    • 10.3.5. Analysis by Year and Type of Funding
    • 10.3.6. Analysis by Type of Circulating Biomarker
    • 10.3.7. Analysis by Target Disease Indication
    • 10.3.8. Analysis by Application Area
    • 10.3.9. Analysis by Geography
    • 10.3.10. Most Active Players: Analysis by Number of Funding Instances
    • 10.3.11. Most Active Players: Analysis by Amount Raised
    • 10.3.12. Most Active Investors: Analysis by Number of Funding Instances

11. PRODUCT COMPETITIVENESS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Methodology
  • 11.3. Assumptions and Key Parameters
  • 11.4. Liquid Biopsy: Product Competitiveness Analysis
    • 11.4.1. Liquid Biopsy Assay Kits
      • 11.4.1.1. Products Offered by Players based in North America
      • 11.4.1.2. Products Offered by Players based in Europe
      • 11.4.1.3. Products Offered by Players based in Asia-Pacific
      • 11.4.1.4. Products Offered by Players based in Rest of the World
    • 11.4.2. Liquid Biopsy Devices
      • 11.4.2.1. Products Offered by Players based in North America
      • 11.4.2.2. Products Offered by Players based in Europe and Asia-Pacific
    • 11.4.3. Liquid Biopsy Software

12. BIG PHARMA INITIATIVES

  • 12.1. Chapter Overview
  • 12.2. Top Pharmaceutical Companies
    • 12.2.1. Analysis by Type of Initiative
    • 12.2.2. Analysis by Stage of Development
    • 12.2.3. Analysis by Type of Product
    • 12.2.4. Analysis by Type of Circulating Biomarker
    • 12.2.5. Analysis by Target Disease Indication
    • 12.2.6. Analysis by Application
    • 12.2.7. Analysis by Application Area

13. KEY ACQUISITION TARGETS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Scoring Criteria and Key Assumptions
  • 13.4. Potential Acquisition Targets in North America
  • 13.5. Potential Acquisition Targets in Europe
  • 13.6. Potential Acquisition Targets in Asia-Pacific and Rest of the World
  • 13.7. Concluding Remarks

14. OTHER NON-INVASIVE CANCER DIAGNOSTICS

  • 14.1. Chapter Overview
  • 14.2. Non-Blood-based Biomarker Detection Tests
  • 14.3. FOBT and Fecal Immunochemical Tests (FIT)
  • 14.4. Pigmented Lesion Assays
  • 14.5. Stool DNA (sDNA)-based Tests
  • 14.6. Volatile Organic Compound (VOC) Detection Tests
  • 14.7. Other Non-Invasive Cancer Diagnostics: Market Landscape

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 15.1. Chapter Overview
  • 15.2. Market Drivers
  • 15.3. Market Restraints
  • 15.4. Market Opportunities
  • 15.5. Market Challenges
  • 15.6. Conclusion

16. GLOBAL LIQUID BIOPSY MARKET

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Global Non-Invasive Cancer Diagnostics Market, (2023-2035)
  • 16.4. Global Liquid Biopsy Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 16.4.1. Scenario Analysis
  • 16.5. Key Market Segmentations
  • 16.6. Dynamic Dashboard

17. LIQUID BIOPSY MARKET, BY APPLICATION

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Early Cancer Diagnosis: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.4. Patient Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.5. Recurrence Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.6. Data Triangulation and Validation

18. LIQUID BIOPSY MARKET, BY TARGET DISEASE INDICATION

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Bladder Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.4. Neurological Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.5. Breast Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.6. Cervical Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.7. Head and Neck Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.8. Leukemia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.9. Liver Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.10. Lung Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.11. Melanoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.12. Nasopharyngeal Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.13. Oesophagus Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.14. Ovarian Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.15. Pancreatic Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.16. Prostate Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.17. Sarcoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.18. Stomach Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.19. Thyroid Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.20. Data Triangulation and Validation

19. LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Cell-Free DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.4. Circulating Tumor DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.5. Extracellular Vesicles: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.6. Other Circulating Biomarkers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.7. Data Triangulation and Validation

20. LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Blood / Plasma Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.4. Other Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.5. Data Triangulation and Validation

21. LIQUID BIOPSY MARKET, BY TYPE OF END-USER

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Hospitals: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.4. Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.5. Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.6. Data Triangulation and Validation

22. LIQUID BIOPSY MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.5. Asia-Pacific and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.6. Data Triangulation and Validation

23. SURVEY INSIGHTS

  • 23.1. Chapter Overview
  • 23.2. Company Specifics of Respondents
  • 23.3. Analysis by Seniority Level of Respondents
  • 23.4. Analysis by Type of Product Portfolio
  • 23.5. Analysis by Type of Products / Services Offered
  • 23.6. Analysis by Stage of Development of Product
  • 23.7. Analysis by Application Area
  • 23.8. Analysis by Likely Market Size

24. CONCLUSION

25. EXECUTIVE INSIGHTS

  • 25.1. Chapter Overview
  • 25.2. Foundation for the National Institutes of Health
    • 25.2.1. Company Snapshot
    • 25.2.2. Interview Transcript
  • 25.3. Bahia Software
    • 25.3.1. Company Snapshot
    • 25.3.2. Interview Transcript
  • 25.4. Genostics
    • 25.4.1. Company Snapshot
    • 25.4.2. Interview Transcript
  • 25.5. Oncophenomics
    • 25.5.1. Company Snapshot
    • 25.5.2. Interview Transcript
  • 25.6. Minomic International
    • 25.6.1. Company Snapshot
    • 25.6.2. Interview Transcript
  • 25.7. IVDiagnostics
    • 25.7.1. Company Snapshot
    • 25.7.2. Interview Transcript
  • 25.8. Tymora Analytical Operations
    • 25.8.1. Company Snapshot
    • 25.8.2. Interview Transcript
  • 25.9. ProXeom
    • 25.9.1. Company Snapshot
    • 25.9.2. Interview Transcript
  • 25.10. MiNDERA
    • 25.10.1. Company Snapshot
    • 25.10.2. Interview Transcript
  • 25.11. Resolution Bioscience
    • 25.11.1. Company Snapshot
    • 25.11.2. Interview Transcript
  • 25.12. Nanostics
    • 25.12.1. Company Snapshot
    • 25.12.2. Interview Transcript
  • 25.13. DermTech
    • 25.13.1. Company Snapshot
    • 25.13.2. Interview Transcript
  • 25.14. iCellate Medical
    • 25.14.1. Company Snapshot
    • 25.14.2. Interview Transcript
  • 25.15. VolitionRx
    • 25.15.1. Company Snapshot
    • 25.15.2. Interview Transcript
  • 25.16. OncoDNA
    • 25.16.1. Company Snapshot
    • 25.16.2. Interview Transcript
  • 25.17. LCM Genect
    • 25.17.1. Company Snapshot
    • 25.17.2. Interview Transcript
  • 25.18. Sienna Cancer Diagnostics
    • 25.18.1. Company Snapshot
    • 25.18.2. Interview Transcript

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS